PURPOSE: To evaluate the clinical outcomes and late effects of radiation therapy (RT) in localized primary orbital mucosa-associated lymphoma tissue (MALT) lymphoma (POML). METHODS AND MATERIALS: From 1989 to 2007, 89 patients with Stage IE POML received RT. The median age was 56 years old. Sites involved conjunctiva (59 patients [66%]), lacrimal gland (20 patients [23%]), and soft tissue (10 patients [11%]). Megavoltage beam(s) was used in 91%, electrons in 7%, and orthovoltage in 2% of cases. The dose given was 25 Gy in 97% and 30 Gy in 3% of patients. Lens shielding was possible in 57% of patients. RESULTS: The median follow-up was 5.9 years. Complete response or unconfirmed complete response was seen in 88 patients (99%). Relapse occurred in 22 patients (25%). First relapse sites were local (2 patients [9%]), in the contralateral orbit (5 patients [23%]), and distant (15 patients [68%]). The 7-year overall survival (OS), cause-specific survival (CSS), relapse-free survival (RFS), and local control (LC) rates were 91%, 96%, 64%, and 97%, respectively. Radiation-related late sequelae were documented in 40 patients (45%). Cataracts were observed in 22 patients (Grade 1 in 2 patients; Grade 3 in 20 patients). The incidence of Grade 3 cataract at 7 years was 25%. Other late sequelae (n = 28) were dry eye(s) (22 patients [Grade 1 in 14 patients; Grade 2 in 2 patients; Grade 3 in 2 patients; n/s in 4 patients), keratitis (3 patients), macular degeneration/cystoid edema (2 patients), and vitreous detachment (1 patient). Five patients developed Grade 3 noncataract late effects. Lens shielding reduced the incidence of Grade 3 cataract and all Grade ≥2 late sequelae. Seventeen patients (16 with cataracts) underwent surgery; 23 patients were treated conservatively. The outcome for managing late effects was generally successful, with 30 patients completely improved, and 9 patients with persisting late sequelae (10%). CONCLUSIONS: POML responds favorably to moderate doses of RT but results in significant late morbidity. The majority of late effects were successfully managed. Lens shielding reduced the risk of cataracts and other late sequelae.
PURPOSE: To evaluate the clinical outcomes and late effects of radiation therapy (RT) in localized primary orbital mucosa-associated lymphoma tissue (MALT) lymphoma (POML). METHODS AND MATERIALS: From 1989 to 2007, 89 patients with Stage IE POML received RT. The median age was 56 years old. Sites involved conjunctiva (59 patients [66%]), lacrimal gland (20 patients [23%]), and soft tissue (10 patients [11%]). Megavoltage beam(s) was used in 91%, electrons in 7%, and orthovoltage in 2% of cases. The dose given was 25 Gy in 97% and 30 Gy in 3% of patients. Lens shielding was possible in 57% of patients. RESULTS: The median follow-up was 5.9 years. Complete response or unconfirmed complete response was seen in 88 patients (99%). Relapse occurred in 22 patients (25%). First relapse sites were local (2 patients [9%]), in the contralateral orbit (5 patients [23%]), and distant (15 patients [68%]). The 7-year overall survival (OS), cause-specific survival (CSS), relapse-free survival (RFS), and local control (LC) rates were 91%, 96%, 64%, and 97%, respectively. Radiation-related late sequelae were documented in 40 patients (45%). Cataracts were observed in 22 patients (Grade 1 in 2 patients; Grade 3 in 20 patients). The incidence of Grade 3 cataract at 7 years was 25%. Other late sequelae (n = 28) were dry eye(s) (22 patients [Grade 1 in 14 patients; Grade 2 in 2 patients; Grade 3 in 2 patients; n/s in 4 patients), keratitis (3 patients), macular degeneration/cystoid edema (2 patients), and vitreous detachment (1 patient). Five patients developed Grade 3 noncataract late effects. Lens shielding reduced the incidence of Grade 3 cataract and all Grade ≥2 late sequelae. Seventeen patients (16 with cataracts) underwent surgery; 23 patients were treated conservatively. The outcome for managing late effects was generally successful, with 30 patients completely improved, and 9 patients with persisting late sequelae (10%). CONCLUSIONS: POML responds favorably to moderate doses of RT but results in significant late morbidity. The majority of late effects were successfully managed. Lens shielding reduced the risk of cataracts and other late sequelae.
Authors: Marco Zschoche; Annette Zimpfer; Björn O Scheef; Anselm M Jünemann; Rudolf F Guthoff; Christian Junghanss; Guido Hildebrandt; Steffen Emmert; Andreas Erbersdobler; Günther Kundt; Vinodh Kakkassery Journal: In Vivo Date: 2020 Jul-Aug Impact factor: 2.155
Authors: Chelsea C Pinnix; Jillian R Gunther; Sarah A Milgrom; Ruben J Cruz Chamorro; L Jeffrey Medeiros; Joseph D Khoury; Behrang Amini; Sattva Neelapu; Hun J Lee; Jason Westin; Nathan Fowler; Loretta Nastoupil; Bouthaina Dabaja Journal: Int J Radiat Oncol Biol Phys Date: 2019-02-12 Impact factor: 7.038
Authors: Chelsea C Pinnix; Bouthaina S Dabaja; Sarah A Milgrom; Grace L Smith; Zeinab Abou; Loretta Nastoupil; Jorge Romaguera; Francesco Turturro; Nathan Fowler; Luis Fayad; Jason Westin; Sattva Neelapu; Michelle A Fanale; Maria A Rodriguez; Frederick Hagemeister; Hun Ju Lee; Yasuhiro Oki; Michael Wang; Felipe Samaniego; Linda Chi; Bita Esmaeli Journal: Head Neck Date: 2017-04-03 Impact factor: 3.147
Authors: Ombretta Annibali; Francesca Chiodi; Chiara Sarlo; Magdalena Cortes; Francesco M Quaranta-Leoni; Carlo Quattrocchi; Antonella Bianchi; Stefano Bonini; Giuseppe Avvisati Journal: Biomed Res Int Date: 2015-09-06 Impact factor: 3.411
Authors: Jonathan Baron; Christopher M Wright; Daniel Y Lee; Maribel Carpenter; Shwetha H Manjunath; César A Briceño; Elise Chong; Amit Maity; John P Plastaras; Ima Paydar Journal: Front Oncol Date: 2021-07-05 Impact factor: 6.244